Mereo BioPharma Group plc

Mereo BioPharma Group plcverified

MREO

Price:

$4.32

Market Cap:

$664.26M

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-64...[Read more]

Industry

Biotechnology

IPO Date

2019-04-24

Stock Exchange

NASDAQ

Ticker

MREO

The Enterprise Value as of September 2024 (TTM) for Mereo BioPharma Group plc (MREO) is 582.99M

According to Mereo BioPharma Group plc’s latest financial reports and current stock price. The company's current Enterprise Value is 582.99M. This represents a change of -54.96% compared to the average of 1.29B of the last 4 quarters.

Mereo BioPharma Group plc (MREO) Historical Enterprise Value (quarterly & annually)

How has MREO Enterprise Value performed in the past?

The mean historical Enterprise Value of Mereo BioPharma Group plc over the last ten years is 470.59M. The current 582.99M Enterprise Value has changed 12.29% with respect to the historical average. Over the past ten years (40 quarters), MREO's Enterprise Value was at its highest in in the March 2024 quarter at 2.35B. The Enterprise Value was at its lowest in in the December 2015 quarter at -76883878.00.

Quarterly (TTM)
Annual

Average

470.59M

Median

330.43M

Minimum

-76883878.00

Maximum

1.47B

Mereo BioPharma Group plc (MREO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Mereo BioPharma Group plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 345.44%

Maximum Annual Enterprise Value = 1.47B

Minimum Annual Increase = -341.12%

Minimum Annual Enterprise Value = -76883878.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20231.47B345.44%
2022330.43M-39.53%
2021546.42M-37.86%
2020879.36M270.97%
2019237.04M-33.96%
2018358.95M18.56%
2017302.75M63.31%
2016185.39M-341.12%

Mereo BioPharma Group plc (MREO) Average Enterprise Value

How has MREO Enterprise Value performed in the past?

The current Enterprise Value of Mereo BioPharma Group plc (MREO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

782.91M

5-year avg

693.03M

10-year avg

470.59M

Mereo BioPharma Group plc (MREO) Enterprise Value vs. Peers

How is MREO’s Enterprise Value compared to its peers?

Mereo BioPharma Group plc’s Enterprise Value is greater than Terns Pharmaceuticals, Inc. (458.36M), greater than PDS Biotechnology Corporation (74.53M), greater than Inozyme Pharma, Inc. (343.89M), greater than HOOKIPA Pharma Inc. (87.25M), less than Day One Biopharmaceuticals, Inc. (1.01B), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than Acumen Pharmaceuticals, Inc. (93.64M), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than eFFECTOR Therapeutics, Inc. (3.83M), greater than Elevation Oncology, Inc. (8.41M), greater than Hepion Pharmaceuticals, Inc. (2.24M),

Build a custom stock screener for Mereo BioPharma Group plc (MREO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mereo BioPharma Group plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mereo BioPharma Group plc (MREO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mereo BioPharma Group plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Mereo BioPharma Group plc's Enterprise Value?

What is the highest Enterprise Value for Mereo BioPharma Group plc (MREO)?

What is the 3-year average Enterprise Value for Mereo BioPharma Group plc (MREO)?

What is the 5-year average Enterprise Value for Mereo BioPharma Group plc (MREO)?

How does the current Enterprise Value for Mereo BioPharma Group plc (MREO) compare to its historical average?